drugset / Trial / NCT00771017
Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer
RandomizedOpen-labelTreatment
Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy, such as bicalutamide, leuprolide, and goserelin, may lessen the amount of androgens made by the body. Vaccine therapy may help the body build an effective immune response to kill tumor cells. It is not yet known whether androgen ablation therapy is more effective with or without vaccine therapy in treating patients with prostate cancer. PURPOSE: This randomized phase II trial is studying androgen ablation therapy to see how well it works when given together with or without vaccine therapy in treating patients with prostate cancer.
Timeline
- Start
- 2008-07
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bicalutamide | Other / unclassified | — | Oral |
| Subject | GALGENPROSTUCEL-L | Vaccine | — | Other |
| Subject | Goserelin | Other / unclassified | — | Intramuscular |
| Subject | LITGENPROSTUCEL-L | Vaccine | — | Other |
| Subject | Leuprolide | Other / unclassified | — | Intramuscular |